Menu
Your Cart

Apostle MiniEnrich Short Fragments Enrichment Kit (20uL x 20 preps)

Apostle MiniEnrich Short Fragments Enrichment Kit (20uL x 20 preps)
Apostle MiniEnrich Short Fragments Enrichment Kit (20uL x 20 preps)
Apostle MiniEnrich Short Fragments Enrichment Kit (20uL x 20 preps)
Apostle MiniEnrich Short Fragments Enrichment Kit (20uL x 20 preps)
Secured Shopping
Best security features
Apostle MiniEnrich Short Fragments Enrichment Kit (20uL x 20 preps)

Apostle MiniEnrich for Enrichment of Short DNA fragments for NIPT and Oncology Applications

Precise DNA sizing can boost sequencing efficiency, reduce cost, improve data quality, and even allow sequencing of low-input samples, while current pervasive DNA sizing approaches are incap- able of differentiating DNA fragments under 200 bp with high resolution (<20 bp). In non-invasive prenatal testing (NIPT), the size distribution of cell-free fetal DNA in maternal plasma (main peak at 143 bp) is significantly different from that of maternal cell-free DNA (main peak at 166 bp). The current pervasive workflow of NIPT and DNA sizing is unable to take advantage of this 20 bp difference, resulting in sample rejection, test inaccuracy, and restricted clinical utility.

The Apostle MiniEnrich Short Fragments Enrichment Kit is a simple, automatable, high-resolution DNA size enrichment workflow on a magnetic nano-platform to exploit this 20 bp size difference and to enrich fetal DNA fragments from maternal blood. Two types of magnetic nanoparticles are included, with one able to filter high-molecular-weight DNA with high resolution and the other able to recover the remaining DNA fragments under the size threshold of interest with >95% yield. Using this method, the average fetal fraction was increased from 13% to 20% after the enrichment, as measured by plasma DNA sequencing. This approach provides a new tool for high-resolution DNA size enrich- ment under 200 bp, which may improve NIPT accuracy by rescuing rejected non-reportable clinical samples, and enable NIPT earlier in pregnancy. It also has the potential to improve non-invasive screening for fetal monogenic disorders, differentiate tumor-related DNA in liquid biopsy and find more applications in auto- immune disease diagnosis.


As published in:

High-resolution DNA size enrichment using a magnetic nano-platform and application in non-invasive prenatal testing. Zhang et al. Analyst. July 2020, 145, 5733-5739  (PDF)


Configuration:  20uL x 20 preps

Cat #: A190925-20


Documentation

Protocol: https://www.apostlebio.com/minienrich/MiniEnrich_protocol_20x50_01.pdf


More information

2024年2月,美国MD Anderson癌症中心科学家团队领衔的一项新临床研究发表在Cell子刊 Cancer Cell (影响因子 50.3),建立了临床证据和方法,使用肿瘤cfDNA 甲基化分析可以有效区分小细胞肺癌(SCLC) 亚型,并用于指导SCLC 治疗方案。 在论著的方法学部分,Apostle MiniMax cfDNA 试剂盒被明确列在“关键商业试剂” (Critical commercial assays)表格中,作出自己应用的贡献。Apostle 艾铂图 MiniMax 游离核酸技术不断在国际上得到广泛的应用,迄今,已发表、被引用 Nature 子刊 4篇 ( Nature Medicine X 2, Nature Communications X 2), Science 子刊 1 篇, PNAS 1 篇,各种临床研究60余篇,作者单位来自60余国际领先的医学研究和临床单位。 祝贺此临床研究团队!期待Apostle 艾铂图技术更好地为人类做贡献。